Hubungan Ekspresi Tumor Infiltrating Lymphocytes dengan Klinikopatologi pada Subtipe Luminal A dan Triple Negative Kanker Payudara di Bali

I Gede Tuban Eling Tulus Widiana; Ida Bagus Made Suryawisesa; I Ketut Widiana

doi:10.24843/JBN.2020.v04.i02.p02

I Gede Tuban Eling Tulus Widiana Residen Bedah Umum, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana / RSUP Sanglah Denpasar
Ida Bagus Made Suryawisesa Divisi Bedah Onkologi, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana / RSUP Sanglah Denpasar
I Ketut Widiana Divisi Bedah Onkologi, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana / RSUP Sanglah Denpasar

DOI: https://doi.org/10.24843/JBN.2020.v04.i02.p02

Abstract

Tujuan: Untuk membuktikan adanya hubungan ekspresi TIL dengan klinikopatologi pada subtipe luminal A dan subtipe TNBC beserta ada tidaknya perbedaan antara kedua subjek tersebut. Metode: Penelitian ini merupakan penelitian observasional, dirancang secara potong-lintang di RSUP Sanglah Denpasar. Kriteria inklusi adalah penderita kanker payudara subtipe luminal A dan subtipe TNBC (triple negative breast cancer) sebagai subjek penelitian. Hasil: Pada penelitian ini terdapat 31 subjek dengan Luminal A dan 40 subyek dengan TNBC. Penelitian ini didapatkan hubungan signifikan antara stadium dengan kadar TIL pada kanker payudara subtipe TNBC (p=0,01). Pada kanker payudara subtipe TNBC stadium tinggi, kemungkinan TIL tinggi 3 kali dibandingkan dengan subjek dengan stadium I-II. Adanya hubungan yang bermakna pada penderita dengan TIL tinggi dengan stadium lanjut pada subtype TNBC dan luminal A (p=0,028; PR 1,8; 95%CI 0,54-5,9). Simpulan: Tidak terdapat hubungan signifikan yang diperoleh antara TIL dengan ukuran tumor, stadium klinis, grade histopatologi pada kanker payudara subtipe luminal A maupun TNBC. Tidak terdapat pula hubungan ukuran tumor dan grading tumor antara kanker payudara dengan subtipe TNBC dan luminal A yang memiliki TIL yang tinggi, tetapi terdapat perbedaan pada stadium tumor.

Downloads

Download data is not yet available.

References

1. Seigel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin. 2015;65: 5-29.
2. International Agency for Research on Cancer (IARC). Cancer Fact Sheets: Breast Cancer, Estimated Incidence, Mortality, And Prevalence Worldwide In 2012. World Health Organization [serial online] 2016 [diakses 26 Agustus 2019]. Diunduh dari: https://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-15.pdf.
3. Kimman M, Norman R, Jan S, dkk. The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev. 2012;13:411-20.
4. Primadi O, Budijanto D, Kurniasih N, dkk. Buletin Jendela Data dan Informasi Kesehatan. Jakarta: Bakti Husada Kementrian Kesehatan RI; 2015.
5. Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far. Genes Dis. 2016;3:114-123.
6. Goldhirsch A, Wood WC, Coates AS, dkk. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011;22:1736-47.
7. Goldhirsch A, Winer EP, Coates AS, dkk. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013;24:2206-23.
8. Dai X, Li T, Bai Z, dkk. Breast Cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929-43.
9. Ladoire S, Arnould L, Apetoh L, dkk. Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. Clin Cancer Res. 2008;14:2413-20.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
11. Loi S. Host Antitumor Immunity Plays a Role in the Survival of Patients with Newly Diagnosed Triple-Negative Breast Cancer. J Clin Oncol. 2014;32:2935-7.
12. Gingras I, Azim HA, Ignatiadis M, dkk. Immunology and Breast Cancer: Toward a New way of Understanding Breast cancer and Developing Novel Therapeutic Strategies. Clin Adv Hematol Oncol. 2015;13:372-82.
13. Salgado R, Denkert C, Demaria S, dkk. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: rcommendations by an international TILs Working Group 2014. Annals Oncol. 2015;26:259-71.
14. García-Teijido P, Cabal ML, Fernández IP, dkk. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016;10: 31-9.
15. Yamaguchi R, Tanaka M, Yano A, dkk. Tumor-infiltrating lymphocytes are pathologic predictors for neoadjuvant chemotherapy in with breast cancer. Hum Pathol. 2012;43:1688-94.
16. Gunawan IP. Hubungan Antara Tumor Infiltrating lymphocytes dengan Gambaran klinikopatologis pada Pasien Triple negative breast cancer di Bali (tesis). Denpasar: Universitas Udayana Denpasar; 2015.
17. Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117:451-60.
18. Denkert C, von Minckwitz G, Darb-Esfahani S, dkk. Tumour-Infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology. 2018;19: 40-50.
19. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Kanker Payudara. Jakarta: Kementrian Kesehatan Indonesia; 2016.
20. Ahn SG, Jeong J, Hong S, dkk. Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med. 2015;49:355-63.
21. Oble DA, Loewe R, Yu P, dkk. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009;9:3.
22. Ghebeh H, Barhoush E, Tulbah A, dkk. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57.
23. Macchetti AH, Marana HR, Silva JS, dkk. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics (Sao Paulo). 2006;61:203-8.
24. Ben‐Shoshan J, Maysel‐Auslender S, Mor A, dkk. Hypoxia controls CD4+, CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol. 2008;38:2412-8.
25. Viale G. The current state of breast cancer classification. Ann Oncol. 2012;23:x207-10.
26. Budczies J, Bockmayr M, Denkert C, dkk. Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res. 2015;1:225-38.
27. Bianchini G, Balko JM, Mayer IA, dkk. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674-90.
28. Li Z, Song W, Rubinstein M, dkk. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018;11: 142.
29. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348: 69-74.
30. Kandoth C, McLellan MD, Vandin F, dkk. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502: 333-9.
31. Gatalica Z, Snyder C, Maney T, dkk. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. Cancer Epidemiol Biomarkers Prev. 2014;23: 2965-70.